Design Principles for Economic Evaluations in Pharmacy

Economic evaluations are designed to systematically approach a “decision problem.” Each decision problem is comprised of a question of which of a set of options appears to be most efficient, where this comparison occurs in terms of both costs and benefits. This approach still leaves significant scope for those conducting the economic evaluation to choose which costs and which benefits are considered to count. The first of these questions is often resolved in terms of who is the study being done for (i.e., who is the funder and what are their requirements). The second of these questions is harder to answer, and there are several factors that determine how appropriate it is to consider more ambitious, final outcomes such as quality-adjusted life years, as opposed to proxy outcomes or those that represent a nexus for treatment decisions within the clinical pathway. Using a series of examples including some from existing recent evaluations in pharmacy settings, this chapter will consider how to apply the logic of economic evaluation to select a form of economic evaluation that is appropriate to the decision problem faced.

[1]  A. Serrano-Blanco,et al.  Cost-Effectiveness of a Community Pharmacist Intervention in Patients with Depression: A Randomized Controlled Trial (PRODEFAR Study) , 2009, PloS one.

[2]  C. Ukwe,et al.  Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes. , 2013, Value in health regional issues.

[3]  S. Marušić,et al.  Economic evaluation of a pharmaceutical care program for elderly diabetic and hypertensive patients in primary health care: a 36-month randomized controlled clinical trial. , 2015, Journal of managed care & specialty pharmacy.

[4]  G. Barton,et al.  An evaluation of a multi‐site community pharmacy–based chronic obstructive pulmonary disease support service , 2015, The International journal of pharmacy practice.

[5]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  O. Freitas,et al.  Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service. , 2011, Arquivos brasileiros de endocrinologia e metabologia.

[7]  M. Sculpher,et al.  Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings. , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

[8]  P. Mazzola,et al.  Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study , 2015, DARU Journal of Pharmaceutical Sciences.

[9]  Francisco Jódar-Sánchez,et al.  Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program , 2015, PharmacoEconomics.

[10]  Martin Eden,et al.  Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER) , 2014, PharmacoEconomics.

[11]  Mark Sculpher,et al.  Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  G. Crealey,et al.  Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD , 2011, International Journal of Clinical Pharmacy.

[13]  B. Claus,et al.  Epidemiology and cost analysis of pharmacist interventions at Ghent University Hospital , 2012, International Journal of Clinical Pharmacy.

[14]  S. Wordsworth,et al.  Cost-minimisation analysis versus cost-effectiveness analysis, revisited. , 2013, Health economics.

[15]  T. Miller,et al.  Cost-Effectiveness of Reducing Glycaemic Episodes Through Community Pharmacy Management of Patients with Type 2 Diabetes Mellitus , 2014, The Journal of Primary Prevention.

[16]  Andrea Manca,et al.  ‘Lost in Translation’ , 2012, PharmacoEconomics.

[17]  M. le Vaillant,et al.  Cost-Effectiveness of a Community Pharmacist-Led Sleep Apnea Screening Program – A Markov Model , 2013, PloS one.

[18]  A. Briggs,et al.  One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services. , 2011, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.